BRPI0614941B8 - benzoazepinas 8-substituídas, composição farmacêutica, kit e seus usos como moduladores de receptores do tipo barreira - Google Patents
benzoazepinas 8-substituídas, composição farmacêutica, kit e seus usos como moduladores de receptores do tipo barreiraInfo
- Publication number
- BRPI0614941B8 BRPI0614941B8 BRPI0614941A BRPI0614941A BRPI0614941B8 BR PI0614941 B8 BRPI0614941 B8 BR PI0614941B8 BR PI0614941 A BRPI0614941 A BR PI0614941A BR PI0614941 A BRPI0614941 A BR PI0614941A BR PI0614941 B8 BRPI0614941 B8 BR PI0614941B8
- Authority
- BR
- Brazil
- Prior art keywords
- barrier
- receptor modulators
- kit
- type receptor
- pharmaceutical composition
- Prior art date
Links
- -1 8-substituted benzoazepines Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010061598 Immunodeficiency Diseases 0.000 abstract 1
- 208000029462 Immunodeficiency disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000005784 autoimmunity Effects 0.000 abstract 1
- 230000004888 barrier function Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 1
- 230000007813 immunodeficiency Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
benzoazepinas 8-substituídas como moduladores de receptores do tipo barreira. a presente invenção refere-se a composições e métodos úteis para modulação de sinalização através de receptores do tipo barreira tlr7 e/ou tlr8. as composições e os métodos são usados no tratamento de auto-imunidade, alergia por inflamação, asma, rejeição a enxerto, enxerto versus doença do hospedeiro, infecção, sépsia, câncer e imunodeficiência.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71000405P | 2005-08-19 | 2005-08-19 | |
US60/710,004 | 2005-08-19 | ||
PCT/US2006/032098 WO2007024612A2 (en) | 2005-08-19 | 2006-08-17 | 8-substituted benzoazepines as toll-like receptor modulators |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0614941A2 BRPI0614941A2 (pt) | 2013-01-01 |
BRPI0614941B1 BRPI0614941B1 (pt) | 2020-11-17 |
BRPI0614941B8 true BRPI0614941B8 (pt) | 2021-05-25 |
Family
ID=37623842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0614941A BRPI0614941B8 (pt) | 2005-08-19 | 2006-08-17 | benzoazepinas 8-substituídas, composição farmacêutica, kit e seus usos como moduladores de receptores do tipo barreira |
Country Status (31)
Country | Link |
---|---|
US (2) | US8153622B2 (pt) |
EP (3) | EP2322510A3 (pt) |
JP (1) | JP5138592B2 (pt) |
KR (2) | KR20130082182A (pt) |
CN (6) | CN104910072A (pt) |
AP (1) | AP2008004386A0 (pt) |
AU (1) | AU2006283620B2 (pt) |
BR (1) | BRPI0614941B8 (pt) |
CA (3) | CA3003143A1 (pt) |
CR (2) | CR9809A (pt) |
DK (1) | DK1940797T3 (pt) |
EA (1) | EA018543B1 (pt) |
EC (1) | ECSP088292A (pt) |
ES (1) | ES2391031T3 (pt) |
HK (1) | HK1122017A1 (pt) |
HR (1) | HRP20120695T1 (pt) |
IL (2) | IL189467A (pt) |
MA (1) | MA29838B1 (pt) |
MX (1) | MX2008002141A (pt) |
MY (1) | MY146567A (pt) |
NO (1) | NO342587B1 (pt) |
NZ (1) | NZ565907A (pt) |
PL (1) | PL1940797T3 (pt) |
PT (1) | PT1940797E (pt) |
RS (1) | RS52447B (pt) |
SI (1) | SI1940797T1 (pt) |
TN (1) | TNSN08076A1 (pt) |
TW (2) | TWI404537B (pt) |
UA (1) | UA92754C2 (pt) |
WO (1) | WO2007024612A2 (pt) |
ZA (1) | ZA200802496B (pt) |
Families Citing this family (162)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI382019B (zh) * | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯 |
ES2438496T3 (es) * | 2008-08-01 | 2014-01-17 | Ventirx Pharmaceuticals, Inc. | Formulaciones de agonistas de receptores de tipo toll y su uso |
EP2358683B1 (en) * | 2008-11-06 | 2015-04-01 | VentiRx Pharmaceuticals, Inc. | Methods of synthesis of benzazepine derivatives |
BR112012003703A2 (pt) * | 2009-08-18 | 2020-12-08 | Ventrix Phramaceuticals, INC. | Benzoazepinas substituídas como moduladores do receptor tipo toll |
JP5756804B2 (ja) * | 2009-08-18 | 2015-07-29 | ベンティアールエックス ファーマシューティカルズ, インコーポレイテッドVentiRx Pharmaceuticals,Inc. | Toll様レセプターモジュレーターとしての置換ベンゾアゼピン |
PL2560658T3 (pl) | 2010-04-21 | 2017-08-31 | Ventirx Pharmaceuticals, Inc. | Wzmacnianie cytotoksyczności komórkowej zależnej od przeciwciał |
US20110293700A1 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Nanocarrier compositions with uncoupled adjuvant |
US9045468B2 (en) | 2010-08-17 | 2015-06-02 | Albany Molecular Research, Inc. | 2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
SG189071A1 (en) * | 2010-10-01 | 2013-05-31 | Ventirx Pharmaceuticals Inc | Therapeutic use of a tlr agonist and combination therapy |
WO2012045089A2 (en) | 2010-10-01 | 2012-04-05 | Ventirx Pharmaceuticals, Inc. | Methods for the treatment of allergic diseases |
WO2012061717A1 (en) | 2010-11-05 | 2012-05-10 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
GB201022049D0 (en) * | 2010-12-29 | 2011-02-02 | Imp Innovations Ltd | Methods |
AU2012205486B2 (en) * | 2011-01-12 | 2017-02-02 | Array Biopharma, Inc. | Substituted benzoazepines as toll-like receptor modulators |
PL2663555T3 (pl) * | 2011-01-12 | 2017-08-31 | Ventirx Pharmaceuticals, Inc. | Podstawione benzoazepiny jako modulatory receptora toll-podobnego |
ES2887303T3 (es) | 2011-04-08 | 2021-12-22 | Janssen Sciences Ireland Unlimited Co | Derivados de pirimidina para el tratamiento de infecciones víricas |
CN112587671A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
US9868955B2 (en) | 2012-09-29 | 2018-01-16 | Dynavax Technologies Corporation | Human toll-like receptor inhibitors and methods of use thereof |
US9228184B2 (en) | 2012-09-29 | 2016-01-05 | Dynavax Technologies Corporation | Human toll-like receptor inhibitors and methods of use thereof |
US9409888B2 (en) * | 2012-12-11 | 2016-08-09 | Hoffmann-La Roche Inc. | Dimeric compounds |
KR101482999B1 (ko) * | 2013-06-17 | 2015-01-14 | 순천향대학교 산학협력단 | 톨-유사 수용체(tlr)에 의해 유도되는 trif-의존성 신호전달 경로의 억제제로서의 (e)-1-(2-(2-니트로 비닐)페닐)피롤리딘(nvpp)을 유효성분으로 포함하는 항염증제 |
JP2017503803A (ja) | 2014-01-10 | 2017-02-02 | シャンハイ バーディー バイオテック インコーポレイテッド | Egfr発現腫瘍を処置するための化合物及び組成物 |
ES2804101T3 (es) | 2014-04-22 | 2021-02-03 | Hoffmann La Roche | Compuestos de 4-amino-imidazoquinolina |
CN112546231A (zh) | 2014-07-09 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
ES2910446T3 (es) | 2014-07-09 | 2022-05-12 | Birdie Biopharmaceuticals Inc | Combinaciones anti-PD-L1 para tratar tumores |
CN112546238A (zh) | 2014-09-01 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
MX2017007955A (es) | 2014-12-16 | 2018-02-19 | Celgene Corp | Formas solidas que comprenden (1e, 4e)-2-amino-n,n-dipropil-8-(4-( pirrolidina-1-carbonil)fenil)-3h-benzo[b]azepina-4-carboxamida, composiciones de las mismas y usos de las mismas. |
JP6644792B2 (ja) * | 2014-12-18 | 2020-02-12 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ベンザゼピンスルホンアミド化合物 |
EP3722297A1 (en) | 2015-03-04 | 2020-10-14 | Gilead Sciences, Inc. | Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds |
HUE042563T2 (hu) * | 2015-03-06 | 2019-07-29 | Hoffmann La Roche | Benzazepin-dikarboxamid vegyületek |
EP3317289B1 (en) | 2015-06-30 | 2021-10-27 | F. Hoffmann-La Roche AG | Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection |
CA2995004A1 (en) | 2015-08-26 | 2017-03-02 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
EP3349757A1 (en) | 2015-09-15 | 2018-07-25 | Gilead Sciences, Inc. | Modulators of toll-like recptors for the treatment of hiv |
EP3350168B1 (en) | 2015-09-17 | 2019-12-18 | H. Hoffnabb-La Roche Ag | Sulfinylphenyl or sulfonimidoylphenyl benzazepines |
CN108367011A (zh) | 2015-11-02 | 2018-08-03 | 文蒂雷克斯药品公司 | 使用tlr8激动剂治疗癌症 |
LT3390441T (lt) | 2015-12-15 | 2021-11-10 | Gilead Sciences, Inc. | Žmogaus imunodeficito virusą neutralizuojantys antikūnai |
CN115350279A (zh) | 2016-01-07 | 2022-11-18 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-her2组合 |
CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-egfr组合 |
CN115554406A (zh) | 2016-01-07 | 2023-01-03 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-cd20组合 |
WO2017202703A1 (en) | 2016-05-23 | 2017-11-30 | F. Hoffmann-La Roche Ag | Benzazepine dicarboxamide compounds with secondary amide function |
EP3464245B1 (en) * | 2016-05-23 | 2020-10-14 | H. Hoffnabb-La Roche Ag | Benzazepine dicarboxamide compounds with tertiary amide function |
BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
CN118178444A (zh) | 2016-05-27 | 2024-06-14 | 吉利德科学公司 | 使用ns5a、ns5b或ns3抑制剂治疗乙型肝炎病毒感染的方法 |
EP3468963B1 (en) | 2016-06-12 | 2021-10-27 | F. Hoffmann-La Roche AG | Dihydropyrimidinyl benzazepine carboxamide compounds |
WO2018002319A1 (en) | 2016-07-01 | 2018-01-04 | Janssen Sciences Ireland Uc | Dihydropyranopyrimidines for the treatment of viral infections |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
AU2017318601B2 (en) | 2016-09-02 | 2020-09-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
SG10202010317VA (en) | 2016-09-29 | 2020-11-27 | Janssen Sciences Ireland Unlimited Co | Pyrimidine prodrugs for the treatment of viral infections and further diseases |
CR20190181A (es) | 2016-10-14 | 2019-08-21 | Prec Biosciences Inc | Meganucleasas diseñadas específicamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b. |
TWI820984B (zh) | 2017-01-31 | 2023-11-01 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
WO2018170179A1 (en) | 2017-03-15 | 2018-09-20 | Silverback Therapeutics, Inc. | Benzazepine compounds, conjugates, and uses thereof |
JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
WO2018232725A1 (en) | 2017-06-23 | 2018-12-27 | Birdie Biopharmaceuticals, Inc. | PHARMACEUTICAL COMPOSITIONS |
AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
TW202024061A (zh) | 2017-08-17 | 2020-07-01 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
KR20200043439A (ko) | 2017-08-22 | 2020-04-27 | 길리애드 사이언시즈, 인코포레이티드 | 치료 헤테로시클릭 화합물 |
CN109694351B (zh) * | 2017-10-23 | 2020-07-28 | 江苏恒瑞医药股份有限公司 | 苯并氮杂*衍生物、其制备方法及其在医药上的应用 |
WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
CN109721597B (zh) * | 2017-10-30 | 2021-05-14 | 上海迪诺医药科技有限公司 | 吡啶并氮杂卓衍生物、其药物组合物及应用 |
KR20200100113A (ko) | 2017-12-15 | 2020-08-25 | 실버백 테라퓨틱스, 인크. | 간염 치료용 항체 구조물-약물 접합체 |
JP7098748B2 (ja) | 2017-12-20 | 2022-07-11 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. | Stingアダプタータンパク質を活性化するホスホン酸結合を有する2’3’環状ジヌクレオチド |
AU2018392213B2 (en) | 2017-12-20 | 2021-03-04 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
PL3752501T3 (pl) | 2018-02-13 | 2023-08-21 | Gilead Sciences, Inc. | Inhibitory pd-1/pd-l1 |
EP3752495B1 (en) | 2018-02-15 | 2023-07-19 | Gilead Sciences, Inc. | Pyridine derivatives and their use for treating hiv infection |
AR114631A1 (es) | 2018-02-16 | 2020-09-30 | Gilead Sciences Inc | Métodos e intermedios para preparar compuestos de piridina |
WO2019165374A1 (en) | 2018-02-26 | 2019-08-29 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
TW201945003A (zh) | 2018-03-01 | 2019-12-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 2,4-二胺基喹唑啉衍生物及其醫學用途 |
WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
EP3781556A1 (en) | 2018-04-19 | 2021-02-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
BR112020026890A2 (pt) | 2018-07-03 | 2021-03-30 | Jiangsu Hengrui Medicine Co., Ltd. | Derivado de piridopirimidina, método de preparação do mesmo e uso médico do mesmo |
WO2020010107A1 (en) | 2018-07-03 | 2020-01-09 | Gilead Sciences, Inc. | Antibodies that target hiv gp120 and methods of use |
JP7199502B2 (ja) | 2018-07-06 | 2023-01-05 | ギリアード サイエンシーズ, インコーポレイテッド | 治療用複素環式化合物 |
WO2020010200A1 (en) | 2018-07-06 | 2020-01-09 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
PT3820572T (pt) | 2018-07-13 | 2023-11-10 | Gilead Sciences Inc | Inibidores pd-1/pd-l1 |
KR20210033492A (ko) | 2018-07-16 | 2021-03-26 | 길리애드 사이언시즈, 인코포레이티드 | Hiv의 치료를 위한 캡시드 억제제 |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
JP2022500414A (ja) | 2018-09-12 | 2022-01-04 | シルバーバック セラピューティックス インコーポレイテッド | 免疫刺激性コンジュゲートにより疾患を処置する方法および組成物 |
WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
CA3116347A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
CN113227089A (zh) | 2018-10-31 | 2021-08-06 | 吉利德科学公司 | 作为hpk1抑制剂的取代的6-氮杂苯并咪唑化合物 |
MX2021009496A (es) | 2019-02-08 | 2021-09-08 | Progeneer Inc | Complejo de colesterol-agonista del receptor 7 u 8 tipo larga distancia, y uso del mismo. |
WO2020176510A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
WO2020176505A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
CN113574063A (zh) | 2019-03-07 | 2021-10-29 | 捷克共和国有机化学与生物化学研究所 | 3’3’-环二核苷酸及其前药 |
US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202231277A (zh) | 2019-05-21 | 2022-08-16 | 美商基利科學股份有限公司 | 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法 |
EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
WO2020255019A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and a quinazoline derivative |
US20220324817A1 (en) | 2019-06-18 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Quinazoline prodrugs for the treatment of viral infections and further diseases |
WO2020255038A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
EP3986474A1 (en) | 2019-06-19 | 2022-04-27 | Silverback Therapeutics, Inc. | Anti-mesothelin antibodies and immunoconjugates thereof |
CR20210687A (es) | 2019-06-25 | 2022-03-03 | Gilead Sciences Inc | PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO |
TW202115056A (zh) | 2019-06-28 | 2021-04-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
US11795210B2 (en) | 2019-07-16 | 2023-10-24 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
KR20220058555A (ko) | 2019-08-15 | 2022-05-09 | 실버백 테라퓨틱스, 인크. | 벤즈아제핀 접합체의 제형 및 이의 용도 |
EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
CN117843811A (zh) | 2019-09-30 | 2024-04-09 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
CA3151322A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
CN118178645A (zh) | 2019-10-18 | 2024-06-14 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
WO2021087064A1 (en) | 2019-10-31 | 2021-05-06 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
KR20220106165A (ko) | 2019-11-26 | 2022-07-28 | 길리애드 사이언시즈, 인코포레이티드 | Hiv의 예방을 위한 캡시드 억제제 |
CN116057068A (zh) | 2019-12-06 | 2023-05-02 | 精密生物科学公司 | 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶 |
JP2023509881A (ja) | 2019-12-24 | 2023-03-10 | カルナバイオサイエンス株式会社 | ジアシルグリセロールキナーゼ調節化合物 |
CA3163386A1 (en) | 2020-01-02 | 2021-07-08 | Qi Wu | Crystal form of pyridopyrimidine derivative and preparation method thereof |
EP4103285A2 (en) | 2020-02-14 | 2022-12-21 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
WO2021168274A1 (en) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
CA3170551A1 (en) | 2020-03-02 | 2021-09-10 | Yong Taik Lim | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
JP2023518433A (ja) | 2020-03-20 | 2023-05-01 | ギリアード サイエンシーズ, インコーポレイテッド | 4’-c-置換-2-ハロ-2’-デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法 |
KR20230006891A (ko) | 2020-05-01 | 2023-01-11 | 길리애드 사이언시즈, 인코포레이티드 | Cd73를 억제하는 2,4-다이옥소피리미딘 화합물 |
EP4153181A1 (en) | 2020-05-21 | 2023-03-29 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
JP2023533915A (ja) | 2020-06-25 | 2023-08-07 | ギリアード サイエンシーズ, インコーポレイテッド | Hivの治療のためのカプシド阻害剤 |
CN116209678A (zh) | 2020-07-01 | 2023-06-02 | 安尔士制药公司 | 抗asgr1抗体缀合物及其用途 |
EP4194010A1 (en) | 2020-08-04 | 2023-06-14 | Progeneer Inc. | Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof |
WO2022031011A1 (ko) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | 동력학적으로 작용하는 아주번트 앙상블 |
EP4194006A1 (en) | 2020-08-04 | 2023-06-14 | Progeneer Inc. | Mrna vaccine comprising adjuvant capable of kinetic control |
CA3186054A1 (en) | 2020-08-07 | 2022-02-10 | Daniel H. BYUN | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
CN116437958A (zh) | 2020-11-11 | 2023-07-14 | 吉利德科学公司 | 鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法 |
AU2022253902A1 (en) | 2021-04-10 | 2023-11-02 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
CA3216459A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
TW202310852A (zh) | 2021-05-13 | 2023-03-16 | 美商基利科學股份有限公司 | TLR8調節化合物及抗HBV siRNA療法之組合 |
TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用FLT3L—Fc融合蛋白之方法 |
KR20240023629A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CR20230585A (es) | 2021-06-23 | 2024-02-19 | Gilead Sciences Inc | Compuestos Moduladores de Diacilglicerol Quinasa. |
WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
AU2022376954A1 (en) | 2021-10-29 | 2024-05-02 | Gilead Sciences, Inc. | Cd73 compounds |
TW202342447A (zh) | 2021-12-03 | 2023-11-01 | 美商基利科學股份有限公司 | 用於hiv病毒感染之治療性化合物 |
CA3235937A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
US20230203071A1 (en) | 2021-12-03 | 2023-06-29 | Zhimin Du | Therapeutic compounds for hiv virus infection |
US20230203202A1 (en) | 2021-12-08 | 2023-06-29 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
US20230220106A1 (en) | 2021-12-08 | 2023-07-13 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ikaros鋅指家族降解劑及其用途 |
WO2023183817A1 (en) | 2022-03-24 | 2023-09-28 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
TW202400172A (zh) | 2022-04-06 | 2024-01-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
WO2024006982A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
WO2024044477A1 (en) | 2022-08-26 | 2024-02-29 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US4002610A (en) * | 1975-09-22 | 1977-01-11 | Mcneil Laboratories, Incorporated | 2-Aminobenzodiazepine-5-ones |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
JPS6487631A (en) | 1987-09-28 | 1989-03-31 | Idemitsu Petrochemical Co | Production of polyarylene sulfide |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
GB8920519D0 (en) | 1989-09-11 | 1989-10-25 | Rhone Poulenc Ltd | New compositions of matter |
US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
ES2173391T3 (es) * | 1996-08-16 | 2002-10-16 | Pfizer | Derivados de 2-aminobenzazepina y su uso para el tratamiento de la inmunodepresion. |
WO2002009748A1 (en) * | 2000-07-31 | 2002-02-07 | Yale University | Innate immune system-directed vaccines |
EP2366389A1 (en) * | 2002-04-08 | 2011-09-21 | Takeda Pharmaceutical Company Limited | Severe sepsis preventive therapeutic agent |
EA200500005A1 (ru) * | 2002-06-12 | 2005-06-30 | Байоджен Айдек Ма Инк. | Способ лечения повреждения, вызванного реперфузией после ишемии, с использованием антагонистов рецептора аденозина |
US20040213264A1 (en) | 2003-04-25 | 2004-10-28 | Nortel Networks Limited | Service class and destination dominance traffic management |
JP2007524615A (ja) * | 2003-06-20 | 2007-08-30 | コーリー ファーマシューティカル ゲーエムベーハー | 低分子トール様レセプター(tlr)アンタゴニスト |
US20050096259A1 (en) * | 2003-10-31 | 2005-05-05 | 3M Innovative Properties Company | Neutrophil activation by immune response modifier compounds |
JP2007513165A (ja) * | 2003-12-02 | 2007-05-24 | スリーエム イノベイティブ プロパティズ カンパニー | Irm化合物を含む併用薬および治療方法 |
US20050226878A1 (en) * | 2003-12-02 | 2005-10-13 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
WO2006026760A2 (en) | 2004-09-02 | 2006-03-09 | 3M Innovative Properties Company | 1-amino imidazo-containing compounds and methods |
TWI382019B (zh) * | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯 |
EP2358683B1 (en) * | 2008-11-06 | 2015-04-01 | VentiRx Pharmaceuticals, Inc. | Methods of synthesis of benzazepine derivatives |
JP5756804B2 (ja) * | 2009-08-18 | 2015-07-29 | ベンティアールエックス ファーマシューティカルズ, インコーポレイテッドVentiRx Pharmaceuticals,Inc. | Toll様レセプターモジュレーターとしての置換ベンゾアゼピン |
BR112012003703A2 (pt) * | 2009-08-18 | 2020-12-08 | Ventrix Phramaceuticals, INC. | Benzoazepinas substituídas como moduladores do receptor tipo toll |
-
2006
- 2006-08-10 TW TW095129414A patent/TWI404537B/zh not_active IP Right Cessation
- 2006-08-10 TW TW102117584A patent/TW201402124A/zh unknown
- 2006-08-17 CA CA3003143A patent/CA3003143A1/en not_active Abandoned
- 2006-08-17 AU AU2006283620A patent/AU2006283620B2/en not_active Ceased
- 2006-08-17 PL PL06801705T patent/PL1940797T3/pl unknown
- 2006-08-17 EP EP20100184139 patent/EP2322510A3/en not_active Ceased
- 2006-08-17 CN CN201510165871.3A patent/CN104910072A/zh active Pending
- 2006-08-17 DK DK06801705.2T patent/DK1940797T3/da active
- 2006-08-17 CA CA2865331A patent/CA2865331C/en active Active
- 2006-08-17 CN CNA2006800380964A patent/CN101309906A/zh active Pending
- 2006-08-17 WO PCT/US2006/032098 patent/WO2007024612A2/en active Application Filing
- 2006-08-17 CN CN201810884657.7A patent/CN109096193A/zh active Pending
- 2006-08-17 CN CN201510192094.1A patent/CN104945323A/zh active Pending
- 2006-08-17 ES ES06801705T patent/ES2391031T3/es active Active
- 2006-08-17 BR BRPI0614941A patent/BRPI0614941B8/pt not_active IP Right Cessation
- 2006-08-17 UA UAA200803390A patent/UA92754C2/ru unknown
- 2006-08-17 CA CA2619581A patent/CA2619581C/en active Active
- 2006-08-17 US US12/064,193 patent/US8153622B2/en active Active
- 2006-08-17 KR KR1020137016949A patent/KR20130082182A/ko not_active Application Discontinuation
- 2006-08-17 EP EP16157513.9A patent/EP3081558A1/en not_active Withdrawn
- 2006-08-17 JP JP2008527127A patent/JP5138592B2/ja active Active
- 2006-08-17 MX MX2008002141A patent/MX2008002141A/es active IP Right Grant
- 2006-08-17 PT PT06801705T patent/PT1940797E/pt unknown
- 2006-08-17 EA EA200800634A patent/EA018543B1/ru unknown
- 2006-08-17 KR KR1020087006590A patent/KR101442846B1/ko active IP Right Grant
- 2006-08-17 NZ NZ565907A patent/NZ565907A/en not_active IP Right Cessation
- 2006-08-17 MY MYPI20080300A patent/MY146567A/en unknown
- 2006-08-17 AP AP2008004386A patent/AP2008004386A0/xx unknown
- 2006-08-17 CN CN201810884424.7A patent/CN109096192A/zh active Pending
- 2006-08-17 CN CN201510118046.8A patent/CN104803915A/zh active Pending
- 2006-08-17 EP EP06801705A patent/EP1940797B1/en active Active
- 2006-08-17 RS RS20120384A patent/RS52447B/en unknown
- 2006-08-17 SI SI200631420T patent/SI1940797T1/sl unknown
-
2008
- 2008-02-12 IL IL189467A patent/IL189467A/en active IP Right Grant
- 2008-02-18 TN TNP2008000076A patent/TNSN08076A1/en unknown
- 2008-03-12 CR CR9809A patent/CR9809A/es unknown
- 2008-03-18 NO NO20081425A patent/NO342587B1/no unknown
- 2008-03-18 ZA ZA200802496A patent/ZA200802496B/xx unknown
- 2008-03-18 MA MA30762A patent/MA29838B1/fr unknown
- 2008-03-18 EC EC2008008292A patent/ECSP088292A/es unknown
- 2008-12-04 HK HK08113230.5A patent/HK1122017A1/xx not_active IP Right Cessation
-
2012
- 2012-03-07 US US13/414,579 patent/US8304407B2/en active Active
- 2012-09-04 HR HRP20120695TT patent/HRP20120695T1/hr unknown
-
2013
- 2013-03-24 IL IL225446A patent/IL225446A0/en unknown
- 2013-06-25 CR CR20130321A patent/CR20130321A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0614941B8 (pt) | benzoazepinas 8-substituídas, composição farmacêutica, kit e seus usos como moduladores de receptores do tipo barreira | |
HK1122018A1 (en) | Aminodiazepines as toll-like receptor modulators | |
BRPI0918868B8 (pt) | compostos moduladores do receptor de nmda e composições compreendendo os mesmos | |
CL2007002513A1 (es) | Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras. | |
BR112014029099A2 (pt) | anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende | |
BRPI0509369A (pt) | azaindóis úteis como inibidores de jak e outras proteìna cinases | |
UY31430A1 (es) | Derivados de piridina y pirazina -83 | |
BRPI0411514A (pt) | antagonistas de receptor toll-like de molécula pequena | |
HN2006009702A (es) | Composicion farmaceutica para el tratamiento del cancer | |
CL2008000690A1 (es) | Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras. | |
CL2007003635A1 (es) | Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer. | |
BRPI0613859A8 (pt) | compostos derivados de nitrocatecol, seu uso e seu processo de preparação, bem como composição farmacêutica | |
CL2008003480A1 (es) | Compuestos derivados de amino-pirimidina, con propiedades inmunomoduladoras y que actuan a traves de tlr7; proceso para preparar los compuestos; compuestos intermediarios; composicion y combinacion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos | |
UY30183A1 (es) | Derivados de quinolina | |
UY29341A1 (es) | Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricación | |
UY32427A (es) | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma | |
BRPI0606132A2 (pt) | formas cristalinas de docetaxel e processos para seu preparo | |
CO6541528A2 (es) | Derivados de la cromenona | |
EA200801343A1 (ru) | Иммуноглобулины, направленные против nogo | |
CR10497A (es) | Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38 | |
CL2008002984A1 (es) | Composicion farmaceutica que comprende micofenolato sodico y su uso para el tratamiento y/o prevencion en enfermedades autoinmunes tales como el rechazo de aloinjertos o xenoinjertos de organos, celulas o tejidos y como antiinflamatorio. | |
BRPI0715070B8 (pt) | uso de escina na produção de preparados farmacêuticos para tratamento de doenças mediadas ou causadas por granulócitos ativados | |
CL2007003223A1 (es) | Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades. | |
DOP2006000015A (es) | Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricación | |
CR10371A (es) | Compuestos heterociclicos apropiados para tratar trastornos que responden a la moduilacion del receptor de serotonina 5ht6 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA. |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/11/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/08/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |